Kuros Biosciences Ltd.
Develops biologic technologies for tissue repair and bone regeneration.
KURN | SW
Overview
Corporate Details
- ISIN(s):
- CH0325814116
- LEI:
- 5299006U5POB2AVTT709
- Country:
- Switzerland
- Address:
- Wagisstraße 25, 8952 Schlieren
- Website:
- https://kurosbio.com/
- Sector:
- Manufacturing
Description
Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2010-09-28 17:45 |
Dr. Hans Stocker (61) will resign as EVP Regulatory Affairs of Cytos Biotechnol…
|
English | 5.0 KB | ||
| 2010-09-28 07:00 |
Cytos Biotechnology establishes strong patent position around core technology f…
|
English | 7.6 KB | ||
| 2010-09-21 12:00 |
Cytos Biotechnology Presents Novel Toll-Like Receptor 9 Agonist CYT003-QbG10 fo…
|
English | 13.0 KB | ||
| 2010-09-07 17:45 |
Cytos Biotechnology to Present at the 2010 Annual Conference of the European Re…
|
English | 3.7 KB | ||
| 2010-07-22 07:00 |
Cytos Biotechnology Second Quarter Report 2010
|
English | 3.7 KB | ||
| 2010-07-15 03:00 |
A*STAR and Cytos Biotechnology establish influenza vaccine collaboration
|
English | 16.0 KB | ||
| 2010-06-08 07:15 |
Cytos Biotechnology Ltd and Intercell AG close the sale of the platform technol…
|
English | 5.9 KB | ||
| 2010-06-04 07:00 |
Cytos Biotechnology Ltd: CYT003-QbG10 phase IIb data presented at EAACI 2010 in…
|
English | 2.5 KB | ||
| 2010-05-21 07:00 |
Cytos Biotechnology Ltd: Placebo-controlled phase II study shows CYT003-QbG10 i…
|
English | 14.4 KB | ||
| 2010-05-06 07:00 |
Cytos Biotechnology sells platform technology for the identification of monoclo…
|
English | 8.1 KB | ||
| 2010-04-30 17:40 |
Harry Welten becomes new CFO at Cytos Biotechnology Ltd
|
English | 5.8 KB | ||
| 2010-04-23 17:45 |
Cytos Biotechnology Ltd: Constitution of the Board of Directors after the Share…
|
English | 4.7 KB | ||
| 2010-04-22 06:45 |
Cytos Biotechnology Ltd First Quarter Report 2010
|
English | 3.2 KB | ||
| 2010-03-22 17:45 |
Jakob Schlapbach (59) will resign as CFO of Cytos Biotechnology Ltd during the …
|
English | 4.6 KB | ||
| 2010-03-04 17:35 |
Cytos Biotechnology Ltd: Dr. Thomas Hecht succeeds Dr. Francois L'Eplattenier a…
|
English | 4.6 KB |
Automate Your Workflow. Get a real-time feed of all Kuros Biosciences Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kuros Biosciences Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kuros Biosciences Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-23 | N/A | Executive member | Sell | None | 1,264,800.00 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 13,344.49 CHF |
| 2025-03-18 | N/A | Non-Executive member | Buy | None | 38,200.00 CHF |
| 2024-12-11 | N/A | Executive member | Sell | None | 4,702,500.00 CHF |
| 2024-11-15 | N/A | Non-Executive member | Buy | None | 925,210.00 CHF |
| 2024-11-14 | N/A | Non-Executive member | Sell | None | 592,000.00 CHF |
| 2024-11-12 | N/A | Executive member | Sell | None | 13,890.86 CHF |
| 2024-09-25 | N/A | Executive member | Sell | None | 8,226,000.00 CHF |
| 2024-09-25 | N/A | Non-Executive member | Sell | None | 3,656,000.00 CHF |
| 2024-09-24 | N/A | Non-Executive member | Buy | None | 223,720.00 CHF |
Peer Companies
